Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression.

Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, Bernaldo de Quirós Fernández S, Lau A, Richards FM, Jodrell DI.

Mol Cancer Ther. 2018 Aug;17(8):1670-1682. doi: 10.1158/1535-7163.MCT-18-0010. Epub 2018 Jun 11.

PMID:
29891488
2.

Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

Koh SB, Wallez Y, Dunlop CR, Bernaldo de Quirós Fernández S, Bapiro TE, Richards FM, Jodrell DI.

Cancer Res. 2018 Jun 1;78(11):3054-3066. doi: 10.1158/0008-5472.CAN-17-3932. Epub 2018 May 7.

PMID:
29735549
3.

Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy.

Jackson RC, Di Veroli GY, Koh SB, Goldlust I, Richards FM, Jodrell DI.

PLoS Comput Biol. 2017 May 3;13(5):e1005529. doi: 10.1371/journal.pcbi.1005529. eCollection 2017 May.

4.

Development of In Vitro Co-Culture Model in Anti-Cancer Drug Development Cascade.

Xu R, Richards FM.

Comb Chem High Throughput Screen. 2017;20(5):451-457. doi: 10.2174/1386207320666170202093538. Review.

PMID:
28155598
5.

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.

Hessmann E, Patzak MS, Klein L, Chen N, Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM, Jodrell DI, Verbeke C, Li X, Heuchel R, Löhr JM, Johnsen SA, Gress TM, Ellenrieder V, Neesse A.

Gut. 2018 Mar;67(3):497-507. doi: 10.1136/gutjnl-2016-311954. Epub 2017 Jan 10.

6.

A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level.

Koh SB, Mascalchi P, Rodriguez E, Lin Y, Jodrell DI, Richards FM, Lyons SK.

J Cell Sci. 2017 Jan 15;130(2):512-520. doi: 10.1242/jcs.195164. Epub 2016 Nov 25.

7.
8.

Combenefit: an interactive platform for the analysis and visualization of drug combinations.

Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, Jodrell DI.

Bioinformatics. 2016 Sep 15;32(18):2866-8. doi: 10.1093/bioinformatics/btw230. Epub 2016 Apr 25.

9.

Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.

Carapuça EF, Gemenetzidis E, Feig C, Bapiro TE, Williams MD, Wilson AS, Delvecchio FR, Arumugam P, Grose RP, Lemoine NR, Richards FM, Kocher HM.

J Pathol. 2016 Jul;239(3):286-96. doi: 10.1002/path.4727. Epub 2016 May 25.

10.

An automated fitting procedure and software for dose-response curves with multiphasic features.

Di Veroli GY, Fornari C, Goldlust I, Mills G, Koh SB, Bramhall JL, Richards FM, Jodrell DI.

Sci Rep. 2015 Oct 1;5:14701. doi: 10.1038/srep14701.

11.

CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.

Koh SB, Courtin A, Boyce RJ, Boyle RG, Richards FM, Jodrell DI.

Cancer Res. 2015 Sep 1;75(17):3583-95. doi: 10.1158/0008-5472.CAN-14-3347. Epub 2015 Jul 3.

12.

The EGFR demonstrates linear signal transmission.

Oyarzún DA, Bramhall JL, López-Caamal F, Richards FM, Jodrell DI, Krippendorff BF.

Integr Biol (Camb). 2014 Aug;6(8):736-42. doi: 10.1039/c4ib00062e.

PMID:
24934872
13.

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.

Bapiro TE, Frese KK, Courtin A, Bramhall JL, Madhu B, Cook N, Neesse A, Griffiths JR, Tuveson DA, Jodrell DI, Richards FM.

Br J Cancer. 2014 Jul 15;111(2):318-25. doi: 10.1038/bjc.2014.288. Epub 2014 May 29.

14.

Design, synthesis, and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes.

Watts CA, Richards FM, Bender A, Bond PJ, Korb O, Kern O, Riddick M, Owen P, Myers RM, Raff J, Gergely F, Jodrell DI, Ley SV.

Chem Biol. 2013 Nov 21;20(11):1399-410. doi: 10.1016/j.chembiol.2013.09.012. Epub 2013 Oct 24.

15.

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.

Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA.

Gut. 2014 Jun;63(6):974-83. doi: 10.1136/gutjnl-2013-305559. Epub 2013 Sep 25.

16.

Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.

Courtin A, Richards FM, Bapiro TE, Bramhall JL, Neesse A, Cook N, Krippendorff BF, Tuveson DA, Jodrell DI.

PLoS One. 2013 Jun 28;8(6):e67330. doi: 10.1371/journal.pone.0067330. Print 2013.

17.

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells.

Lin Y, Richards FM, Krippendorff BF, Bramhall JL, Harrington JA, Bapiro TE, Robertson A, Zheleva D, Jodrell DI.

Br J Cancer. 2012 Nov 6;107(10):1692-701. doi: 10.1038/bjc.2012.450. Epub 2012 Oct 4.

18.

Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo.

Richards FM, Tape CJ, Jodrell DI, Murphy G.

PLoS One. 2012;7(7):e40597. doi: 10.1371/journal.pone.0040597. Epub 2012 Jul 11.

19.

A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.

Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, Cook N, Jacobetz MA, Smith DM, Tuveson DA, Griffiths JR, Jodrell DI.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1243-53. doi: 10.1007/s00280-011-1613-0. Epub 2011 Mar 23.

20.

Zebrafish based assays for the assessment of cardiac, visual and gut function--potential safety screens for early drug discovery.

Berghmans S, Butler P, Goldsmith P, Waldron G, Gardner I, Golder Z, Richards FM, Kimber G, Roach A, Alderton W, Fleming A.

J Pharmacol Toxicol Methods. 2008 Jul-Aug;58(1):59-68. doi: 10.1016/j.vascn.2008.05.130. Epub 2008 Jun 8.

PMID:
18585469
21.

Validation of the use of zebrafish larvae in visual safety assessment.

Richards FM, Alderton WK, Kimber GM, Liu Z, Strang I, Redfern WS, Valentin JP, Winter MJ, Hutchinson TH.

J Pharmacol Toxicol Methods. 2008 Jul-Aug;58(1):50-8. doi: 10.1016/j.vascn.2008.04.002. Epub 2008 May 2.

PMID:
18541443
22.

GBR12909 possesses anticonvulsant activity in zebrafish and rodent models of generalized epilepsy but cardiac ion channel effects limit its clinical utility.

Goldsmith P, Golder Z, Hunt J, Berghmans S, Jones D, Stables JP, Murphree L, Howden D, Newton PE, Richards FM.

Pharmacology. 2007;79(4):250-8. Epub 2007 Apr 27.

PMID:
17476122
23.

Identification of novel VHL targets that are associated with the development of renal cell carcinoma.

Abdulrahman M, Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Wiesener MS, Richards FM, Johnson CM, Latif F, Maher ER.

Oncogene. 2007 Mar 8;26(11):1661-72. Epub 2006 Sep 25.

PMID:
17001320
24.

The elusive multiple self-healing squamous epithelioma (MSSE) gene: further mapping, analysis of candidates, and loss of heterozygosity.

Bose S, Morgan LJ, Booth DR, Goudie DR, Ferguson-Smith MA, Richards FM.

Oncogene. 2006 Feb 2;25(5):806-12.

PMID:
16170343
25.

Identification of novel VHL target genes and relationship to hypoxic response pathways.

Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM, Johnson CM, Maher ER.

Oncogene. 2005 Jun 30;24(28):4549-58.

PMID:
15824735
26.

Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma.

Morris MR, Maina E, Morgan NV, Gentle D, Astuti D, Moch H, Kishida T, Yao M, Schraml P, Richards FM, Latif F, Maher ER.

J Clin Pathol. 2004 Jul;57(7):706-11.

27.

Molecular pathology of von HippelLindau disease and the VHL tumour suppressor gene.

Richards FM.

Expert Rev Mol Med. 2001 Mar 19;2001:1-27. No abstract available.

PMID:
14987375
28.

John Tileston Edsall: some selected biography and personal reminiscences.

Gurd FR, Richards FM.

Biophys Chem. 2003;100(1-3):49-59.

PMID:
12646348
29.

Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands.

Suriano G, Oliveira C, Ferreira P, Machado JC, Bordin MC, De Wever O, Bruyneel EA, Moguilevsky N, Grehan N, Porter TR, Richards FM, Hruban RH, Roviello F, Huntsman D, Mareel M, Carneiro F, Caldas C, Seruca R.

Hum Mol Genet. 2003 Mar 1;12(5):575-82.

PMID:
12588804
30.

John T. Edsall and Advances in Protein Chemistry.

Eisenberg DS, Kuriyan J, Richards FM.

Adv Protein Chem. 2002;62:xi-xiv. No abstract available.

PMID:
12418097
31.

Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter.

Zatyka M, Morrissey C, Kuzmin I, Lerman MI, Latif F, Richards FM, Maher ER.

J Med Genet. 2002 Jul;39(7):463-72.

32.

Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.

Cancer Res. 2002 Jul 1;62(13):3803-11. Erratum in: Cancer Res. 2015 Sep 15;75(18):3993.

33.

Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer.

Porter TR, Richards FM, Houlston RS, Evans DG, Jankowski JA, Macdonald F, Norbury G, Payne SJ, Fisher SA, Tomlinson I, Maher ER.

Oncogene. 2002 Mar 14;21(12):1928-33.

34.

Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.

Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER.

Cancer Res. 2001 Oct 1;61(19):7277-81.

35.

MET mutation and familial gastric cancer.

Chen JD, Kearns S, Porter T, Richards FM, Maher ER, Teh BT.

J Med Genet. 2001 Aug;38(8):E26. No abstract available.

36.

Methylene as a possible universal footprinting reagent that will include hydrophobic surface areas: overview and feasibility: properties of diazirine as a precursor.

Richards FM, Lamed R, Wynn R, Patel D, Olack G.

Protein Sci. 2000 Dec;9(12):2506-17. Erratum in: Protein Sci. 2004 Jun;13(6):1706.

37.

Germline mutation analysis of the transforming growth factor beta receptor type II (TGFBR2) and E-cadherin (CDH1) genes in early onset and familial colorectal cancer.

Verma L, Porter TR, Richards FM, Rajpar MH, Evans DG, Macdonald F, Maher ER.

J Med Genet. 2001 Feb;38(2):E7. No abstract available.

38.

Protein packing: dependence on protein size, secondary structure and amino acid composition.

Fleming PJ, Richards FM.

J Mol Biol. 2000 Jun 2;299(2):487-98.

PMID:
10860754
39.

Familial gastric cancer: overview and guidelines for management.

Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, Lewis FR, Huntsman DG, Pharoah PD, Jankowski JA, MacLeod P, Vogelsang H, Keller G, Park KG, Richards FM, Maher ER, Gayther SA, Oliveira C, Grehan N, Wight D, Seruca R, Roviello F, Ponder BA, Jackson CE.

J Med Genet. 1999 Dec;36(12):873-80. Review.

40.

Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer.

Richards FM, McKee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA, McKeown C, Sanders DS, Maher ER.

Hum Mol Genet. 1999 Apr;8(4):607-10.

PMID:
10072428
41.

An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects.

Webster AR, Richards FM, MacRonald FE, Moore AT, Maher ER.

Am J Hum Genet. 1998 Oct;63(4):1025-35.

42.

Molecular genetic analysis of von Hippel-Lindau disease.

Richards FM, Webster AR, McMahon R, Woodward ER, Rose S, Maher ER.

J Intern Med. 1998 Jun;243(6):527-33. Review.

43.
44.

Mapping the multiple self-healing squamous epithelioma (MSSE) gene and investigation of xeroderma pigmentosum group A (XPA) and PATCHED (PTCH) as candidate genes.

Richards FM, Goudie DR, Cooper WN, Jene Q, Barroso I, Wicking C, Wainwright BJ, Ferguson-Smith MA.

Hum Genet. 1997 Dec;101(3):317-22.

PMID:
9439661
45.

Protein stability: still an unsolved problem.

Richards FM.

Cell Mol Life Sci. 1997 Oct;53(10):790-802. Review.

PMID:
9413550
46.
47.

Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors.

Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara NA, Maher ER.

Am J Hum Genet. 1997 Apr;60(4):765-71.

48.

Whatever happened to the fun? An autobiographical investigation.

Richards FM.

Annu Rev Biophys Biomol Struct. 1997;26:1-25. No abstract available.

PMID:
9241411
49.

Mobile unnatural amino acid side chains in the core of staphylococcal nuclease.

Wynn R, Harkins PC, Richards FM, Fox RO.

Protein Sci. 1996 Jun;5(6):1026-31.

50.

Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis.

Richards FM, Schofield PN, Fleming S, Maher ER.

Hum Mol Genet. 1996 May;5(5):639-44.

PMID:
8733131

Supplemental Content

Loading ...
Support Center